MTEX vs. IVA, NVCT, DBVT, INZY, TARA, MGX, ELUT, ENTA, IGMS, and CABA
Should you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Inventiva (IVA), Nuvectis Pharma (NVCT), DBV Technologies (DBVT), Inozyme Pharma (INZY), Protara Therapeutics (TARA), Metagenomi (MGX), Elutia (ELUT), Enanta Pharmaceuticals (ENTA), IGM Biosciences (IGMS), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.
Mannatech vs.
Inventiva (NASDAQ:IVA) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
Inventiva has a net margin of 0.00% compared to Mannatech's net margin of -1.26%. Inventiva's return on equity of 0.00% beat Mannatech's return on equity.
Mannatech received 294 more outperform votes than Inventiva when rated by MarketBeat users. However, 80.00% of users gave Inventiva an outperform vote while only 76.77% of users gave Mannatech an outperform vote.
19.1% of Inventiva shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Inventiva has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
In the previous week, Inventiva had 1 more articles in the media than Mannatech. MarketBeat recorded 1 mentions for Inventiva and 0 mentions for Mannatech. Inventiva's average media sentiment score of 0.75 beat Mannatech's score of -0.50 indicating that Inventiva is being referred to more favorably in the media.
Inventiva currently has a consensus price target of $13.25, suggesting a potential upside of 513.43%. Given Inventiva's stronger consensus rating and higher probable upside, equities research analysts clearly believe Inventiva is more favorable than Mannatech.
Mannatech has higher revenue and earnings than Inventiva.
Summary
Inventiva beats Mannatech on 11 of the 16 factors compared between the two stocks.
Get Mannatech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mannatech Competitors List
Related Companies and Tools
This page (NASDAQ:MTEX) was last updated on 1/21/2025 by MarketBeat.com Staff
